- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, announced today that Celera Corporation has extended its license agreement of Nanogen's patent portfolio in molecular biology to develop additional diagnostic products.
Celera Corporation will use Nanogen's Minor Groove Binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This is an expansion of the original license agreement, signed in 2004, in which Celera licensed the technology for development of a hepatitis C genotyping products for individual patient management, monitoring and treatment. Under the Agreement, Celera Corporation will pay Nanogen an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.
"The Celera license expands our current license into new and exciting molecular diagnostic applications," said Howard Birnsdorf, Nanogen CEO. "Our MGB technology has been licensed to a number of companies and the expanded field for Celera strongly supports the value of our technology in real-time PCR."
Nanogen's MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.
About Nanogen, Inc.
Nanogen provides innovative, high-quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare.
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.celera.com.
For more information, please click here
Chief Financial Officer
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
High-tech nanofibres could help nutrients in food hit the spot June 17th, 2015